No material company-specific disclosures were available in recent briefings at the time of this report's generation. The analysis below draws on SEC filings, Form 4 insider transaction data, and prevailing macroeconomic indicators as of the generation date [Brief - 2026-06-04].
As of 31 March 2026, Gilead Sciences reported trailing twelve-month revenue of $29.74 billion, representing year-over-year growth of approximately 4.4%. Net income over the same period reached $9.22 billion, with a net margin of 31.0% and an operating margin of 34.9%. Gross margin stood at 66.5%. Earnings per share grew 54.8% year-over-year on a TTM basis. The company held $7.63 billion in cash against total debt of $23.49 billion. The price-to-earnings ratio was recorded at 17.86, with a market capitalisation of approximately $163.0 billion [SEC 10-Q - GILD - 2026-03-31].
Insider activity over the past 30 days comprised 16 recorded transactions with a net directional bias toward disposal, totalling a net sold value of approximately $2.64 million. No significant institutional 13F position changes were available in the provided context for this reporting period [SEC Form 4 - GILD - 2026-07].
The prevailing macroeconomic environment features a 10-year US Treasury yield of 4.48% and a 2-year yield of 4.17%, reflecting a normal yield curve configuration [FRED DGS10] [FRED DGS2]. The spread of 31 basis points between the two tenors indicates a positively sloped term structure as of the generation date.
This report was generated in response to recent insider transaction activity recorded under SEC Form 4 filings for Gilead Sciences during July 2026 [SEC Form 4 - GILD - 2026-07].